Amarin Corp PLC (AMRN)
0.50
-0.02
(-3.85%)
USD |
NASDAQ |
Nov 15, 16:00
0.5052
+0.01
(+1.04%)
After-Hours: 20:00
Amarin Research and Development Expense (TTM): 20.68M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 20.68M |
| June 30, 2024 | 21.24M |
| March 31, 2024 | 22.14M |
| December 31, 2023 | 22.22M |
| September 30, 2023 | 21.67M |
| June 30, 2023 | 22.33M |
| March 31, 2023 | 26.04M |
| December 31, 2022 | 30.41M |
| September 30, 2022 | 30.92M |
| June 30, 2022 | 32.98M |
| March 31, 2022 | 29.98M |
| December 31, 2021 | 29.31M |
| September 30, 2021 | 32.06M |
| June 30, 2021 | 34.45M |
| March 31, 2021 | 38.06M |
| December 31, 2020 | 38.96M |
| September 30, 2020 | 41.55M |
| June 30, 2020 | 40.27M |
| March 31, 2020 | 37.43M |
| December 31, 2019 | 34.39M |
| September 30, 2019 | 35.20M |
| June 30, 2019 | 40.35M |
| March 31, 2019 | 51.38M |
| December 31, 2018 | 55.90M |
| September 30, 2018 | 55.94M |
| Date | Value |
|---|---|
| June 30, 2018 | 52.56M |
| March 31, 2018 | 48.10M |
| December 31, 2017 | 47.16M |
| September 30, 2017 | 45.39M |
| June 30, 2017 | 48.18M |
| March 31, 2017 | 47.07M |
| December 31, 2016 | 49.98M |
| September 30, 2016 | 53.14M |
| June 30, 2016 | 52.75M |
| March 31, 2016 | 52.18M |
| December 31, 2015 | 51.06M |
| September 30, 2015 | 50.15M |
| June 30, 2015 | 51.52M |
| March 31, 2015 | 51.23M |
| December 31, 2014 | 50.33M |
| September 30, 2014 | 54.49M |
| June 30, 2014 | 56.86M |
| March 31, 2014 | 62.62M |
| December 31, 2013 | 72.75M |
| September 30, 2013 | 75.37M |
| June 30, 2013 | 79.46M |
| March 31, 2013 | 76.04M |
| December 31, 2012 | 58.96M |
| September 30, 2012 | 45.69M |
| June 30, 2012 | 30.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
20.68M
Minimum
Sep 2024
41.55M
Maximum
Sep 2020
30.35M
Average
30.67M
Median
Research and Development Expense (TTM) Benchmarks
| Trinity Biotech PLC | 4.366M |
| Adaptimmune Therapeutics PLC | 143.17M |
| Akari Therapeutics PLC | 8.848M |
| NuCana PLC | 35.08M |
| TC BioPharm (Holdings) PLC | -- |